-
Sep 4, 2024 | 
acrjournals.onlinelibrary.wiley.com | Jane Kang |Howard F. Andrews |Jon Giles |Katherine P Liao
Supporting Information Filename Description acr25424-sup-0001-Disclosureform.pdfPDF document, 840.5 KB Disclosure Form acr25424-sup-0002-Supinfo.zipZip archive, 94.8 KB Appendix S1: Supporting Information
-
Jun 24, 2024 | 
arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Jun 24, 2024 | arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Jun 24, 2024 | arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Dec 7, 2023 | 
acrjournals.onlinelibrary.wiley.com | Jason L. Vassy |Rachel Knevel MD |Katherine P Liao
Corresponding Author Katherine P. Liao MD, MPH Department of Medicine, Veterans Affairs Boston Healthcare System Department of Medicine, Harvard Medical School Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital Department of Biomedical Informatics, Harvard Medical School Corresponding author: Katherine P.
-
Nov 8, 2023 | 
nature.com | fan zhang |Anna Jonsson |Michelle Curtis |Maria Gutierrez-Arcelus |Javier Rangel-Moreno |Kathryne E. Marks | +18 more
AbstractRheumatoid arthritis is a prototypical autoimmune disease that causes joint inflammation and destruction1. There is currently no cure for rheumatoid arthritis, and the effectiveness of treatments varies across patients, suggesting an undefined pathogenic diversity1,2. Here, to deconstruct the cell states and pathways that characterize this pathogenic heterogeneity, we profiled the full spectrum of cells in inflamed synovium from patients with rheumatoid arthritis.
-
May 29, 2023 | 
onlinelibrary.wiley.com | Feicheng Wang |Nathan Palmer |Katherine P Liao |Kun-Hsing Yu
Abstract Rheumatoid arthritis (RA) affects 24.5 million people worldwide and has been associated with increased cancer risks. However, the extent to which the observed risks are related to the pathophysiology of rheumatoid arthritis or its treatments is unknown. Leveraging nationwide health insurance claims data with 85.97 million enrollees across 8 years, we identified 92 864 patients without cancers at the time of rheumatoid arthritis diagnoses.
-
May 25, 2023 | 
nature.com | Katherine P Liao
AbstractThe association between chronic inflammation and increased risk of cardiovascular disease in rheumatoid arthritis (RA) is well established. In the general population, inflammation is an established independent risk factor for cardiovascular disease, and much interest is placed on controlling inflammation to reduce cardiovascular events.
-
Apr 13, 2023 | 
nature.com | Harrison Zhang |Jacqueline P. Honerlaw |Sehi L’Yi |Yuk-Lam Ho |Vidul Ayakulangara Panickan |Katherine P Liao | +4 more
The value of large-scale, real-world data — from electronic health records (EHRs), for example — has been used to establish vaccine efficacy, to elucidate the genetic etiologies of diseases, and to advance epidemiological research1,2,3. Real-world data also have the potential to capture the wide spectrum of clinical features attributed to post-acute sequalae of SARS-CoV-2, also called long COVID, in diverse patient populations4.
